# A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects

> **NCT02692781** · PHASE1 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** MOD-6031
- **OTHER:** Placebo control

## Key facts

- **NCT ID:** NCT02692781
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-12-15
- **Final completion:** 2016-12-15
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02692781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02692781, "A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT02692781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*